Agilent Technologies Inc. announced that it has entered into an exclusive supply agreement with LipoScience Inc. to provide nuclear magnetic resonance (NMR) components for LipoScience’s Vantera Clinical Analyzer. The analyzer is the first fully-automated NMR diagnostic platform designed specifically for the clinical laboratory and cleared by the U.S. Food and Drug Administration.
The Vantera Clinical Analyzer combines proprietary signal-processing algorithms and NMR spectroscopic detection to identify and quantify concentrations of lipoproteins and, potentially, small-molecule metabolites.
“We are extraordinarily pleased to join forces with LipoScience to provide key components for this leading-edge diagnostic platform,” said Nick Roelofs, president of Agilent’s Life Sciences Group.
“LipoScience is pioneering a new field of personalized diagnostics based on NMR technology. Broadening access to our proprietary diagnostic tests is central to our vision of becoming a clinical standard of care. We value Agilent’s NMR expertise and look forward to partnering with them in our efforts to decentralize our NMR clinical analyzer to leading clinical laboratories and academic centers of excellence,” added Richard O. Brajer, chief executive officer of LipoScience.
Date: September 10, 2012
Source: Agilent Technologies Inc.
Filed Under: Drug Discovery
